Some research studies have highlighted the benefits of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL and 68Ga-FAPI-04 (fibroblast activating protein inhibitor) in diagnosing and assessing the treatment of ovarian cancer [48,49]. The gene discussed is FOLH1; the disease is ovarian carcinoma.